Related Experiment Video

Updated: Aug 15, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Comparison of delayed administration of competitive and uncompetitive antagonists in preventing NMDA

D I Levy1, S A Lipton

  • 1Department of Neurology, Children's Hospital, Boston, MA 02115.

Neurology
|May 1, 1990
PubMed

Insights

Delayed administration of MK-801, an uncompetitive NMDA antagonist, protected neurons from injury hours after insult. Competitive antagonists like APV were only effective if given immediately, suggesting MK-801 offers neuroprotection advantages.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • N-methyl-D-aspartate (NMDA) receptor activation contributes to neuronal damage from conditions like hypoxia-ischemia, hypoglycemia, and trauma.
  • Excitotoxicity, mediated by NMDA receptors, is a key mechanism in various neurological injuries.
  • Rat retinal ganglion cells provide a model system for studying excitotoxicity and potential neuroprotective agents.

Purpose of the Study:

  • To compare the efficacy of delayed administration of competitive (APV) and uncompetitive (MK-801) NMDA receptor antagonists in preventing glutamate-induced neuronal injury.
  • To determine if the timing of antagonist administration influences its neuroprotective effect against NMDA receptor-mediated toxicity.
  • To evaluate the potential therapeutic advantage of uncompetitive NMDA antagonists in post-insult scenarios.

Main Methods:

  • Utilized an in vitro model of identified rat retinal ganglion cell neurons.
  • Induced excitotoxicity using glutamate to mimic endogenous neurotoxins.
  • Administered maximally protective doses of 2-amino-5-phosphonovalerate (APV) and MK-801 at different time points post-insult (immediately vs. 1-4 hours later).

Main Results:

  • Both APV and MK-801 prevented neuronal cell death when administered within minutes of toxin exposure.
  • MK-801 demonstrated significant neuroprotection when administered 1 to 4 hours after the insult.
  • APV did not provide significant protection when administered 1 to 4 hours after the insult.

Conclusions:

  • Uncompetitive NMDA antagonists like MK-801 may offer a therapeutic window for neuroprotection when administered hours after a neurological injury.
  • The timing of administration is critical for the efficacy of NMDA receptor antagonists in mitigating excitotoxicity.
  • Delayed administration of uncompetitive NMDA antagonists presents a potential advantage over competitive antagonists in treating certain neurological conditions.

More Related Videos

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity07:11

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity

Published on: September 19, 2025

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...